Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in Melanoma and NSCLC with Brain Metastases
NCT02085070Phase 2Completed
- Sponsor
- Yale University
- Start
- Mar 2014
- Primary completion
- Feb 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of pembrolizumab in melanoma and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Yale University. Primary endpoint: Overall Response in the Brain by mRECIST at 8 weeks. Started Mar 2014; status: completed.
02
Drugs
03
Conditions
melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02085070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02085070.